HOME
기자가 쓴 기사 더보기
Hospira Symbiq One-Channel and Two-Channel Infusers: Class I Recall
(편집자 주: 병원의료기기 회사인 호스피라(Hospira) 제품 '심비크' (Symbiq) 산소주입기의 심각한 문제점이 발견 되었다.)
AUDIENCE: Risk Manager
ISSUE: Potential for the device to fail to detect air in line at the end of an infusion. Failure to detect air in line may result in the delivery of air to the patient, resulting in serious injury or death.
BACKGROUND: The Symbiq Infusion System is an infusion pump intended for the delivery of fluids, solutions, drugs, agents, nutritionals, electrolytes, blood and blood products via parenteral, enteral, intravenous, intra-arterial, subcutaneous, epidural or irrigation routes of administration.
RECOMMENDATION: Hospira mailed clinical bulletins to affected customers on April 9, 2010, and an updated clinical bulletin on June 11, 2010. In the June 11, 2010 letter, Hospira states the user does not have to remove or stop using the Symbiq infusion pump, and provided recommended mitigation actions.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
| 인기기사 | 더보기 + |
-
1 셀루메드, 최대주주 '티디랜드마크조합1호'로 변경 -
2 2026년, '생물보안법' '비만치료제 & CDMO 시장 성장’ 등 통해 바이오산업 재편 -
3 종근당바이오,보툴리눔독소A형 중국3상서 유효성·안전성 입증 -
4 프레스티지바이오파마,췌장암 항체신약 글로벌 임상 1/2a상 진행 -
5 지아이이노베이션,아토피성 피부염 차세대 이중융합 파이프라인 특허 출원 -
6 인투셀, 임원 승진인사 단행 -
7 알테오젠,Tesaro와 피하주사 제형 ‘도스탈리맙’ 개발 라이선스 계약 -
8 큐라클,당뇨병성 신증치료제 'CU01-1001' 임상2b상서 유효성 확인 -
9 이수앱지스,PNH 치료제 ‘ISU305’ 러시아 허가-기술수출 성과 -
10 엔젠바이오, LG AI연구원 ‘엑사원 패스 2.0’ 라이선스 계약 체결
| 인터뷰 | 더보기 + |
| PEOPLE | 더보기 + |
| 컬쳐/클래시그널 | 더보기 + |
|
서울시 서초구 서초대로 115 정다운빌딩 4층 TEL : 02-3270-0114 FAX : 02-3270-0189 E-mail : webmaster@yakup.com |
발행일 : 1954. 03. 29 등록일 : 2016. 05. 02 대표이사 : 함태원 발행 · 편집인 : 함태원 등록번호 : 서울,아04071 |
사업자등록번호 : 106-81-10940 통신사업자신고번호 : 제2022-서울서초-2586호 청소년보호책임자 : 이종운
Copyright © Yakup.com All rights reserved.
|
- 약업신문 편집국 기자 news@yakup.com
- 입력 2010.09.13 06:18 수정 2010.09.26 02:27
Hospira Symbiq One-Channel and Two-Channel Infusers: Class I Recall
(편집자 주: 병원의료기기 회사인 호스피라(Hospira) 제품 '심비크' (Symbiq) 산소주입기의 심각한 문제점이 발견 되었다.)
AUDIENCE: Risk Manager
ISSUE: Potential for the device to fail to detect air in line at the end of an infusion. Failure to detect air in line may result in the delivery of air to the patient, resulting in serious injury or death.
BACKGROUND: The Symbiq Infusion System is an infusion pump intended for the delivery of fluids, solutions, drugs, agents, nutritionals, electrolytes, blood and blood products via parenteral, enteral, intravenous, intra-arterial, subcutaneous, epidural or irrigation routes of administration.
RECOMMENDATION: Hospira mailed clinical bulletins to affected customers on April 9, 2010, and an updated clinical bulletin on June 11, 2010. In the June 11, 2010 letter, Hospira states the user does not have to remove or stop using the Symbiq infusion pump, and provided recommended mitigation actions.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
무단 전재·복사·배포 등을 금지합니다.